secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apellis Pharmaceuticals, Inc. (APLS)
CIK:        0001492422
Form:       8-K
Filed at:   2025-04-21T23:59:59+00:00
Accession:  0001193125-25-086304
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Apellis appoints Craig A. Wheeler to Board, effective April 17, 2025
--------------------------------------------------------------------

- Craig A. Wheeler elected as Class III director; will serve until 2026 annual meeting.
- Appointed to Audit Committee effective May 1, 2025; determined independent under Nasdaq rules.
- Received option for 28,195 shares at $18.20 (3-year vest) and 16,483 RSUs (1-year vest).
- Wheeler is former CEO of Momenta Pharmaceuticals (acquired by J&J) and current CEO of Headwaters Biotech Advisors.
- No arrangements or family relationships with existing directors or executive officers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1492422/000119312525086304/0001193125-25-086304-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1492422/000119312525086304/d918674d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-086304

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer